| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946292 | JAVELIN PHARMS INC | Formulations of low dose diclofenac and beta-cyclodextrin |
Mar, 2027
(3 years from now) | |
Dyloject is owned by Javelin Pharms Inc.
Dyloject contains Diclofenac Sodium.
Dyloject has a total of 1 drug patent out of which 0 drug patents have expired.
Dyloject was authorised for market use on 23 December, 2014.
Dyloject is available in solution;intravenous dosage forms.
Dyloject can be used as management of pain.
The generics of Dyloject are possible to be released after 22 March, 2027.
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Management of pain
Dosage: SOLUTION;INTRAVENOUS
How can I launch a generic of DYLOJECT before it's drug patent expiration?
More Information on Dosage
DYLOJECT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic